Novo Nordisk (NVO) and Pfizer (PFE) stand out as the cheapest large-cap healthcare names in 2026, trading at forward price-to-earnings multiples of 14x and 8x, respectively. Both companies currently grapple with significant headwinds—including drug pricing reforms and patent cliffs—but maintain strong free cash flow and upcoming data catalysts, according to data from 24/7 Wall St.
Why Are Novo Nordisk and Pfizer Trading at Bargain Multiples?
Value investors are increasingly eyeing the healthcare sector as a “bargain bin” following a period of sector-wide multiple compression. According to 24/7 Wall St., the downward pressure stems from a combination of post-COVID-19 hangovers, evolving drug pricing policies, and the looming threat of patent cliffs. For Novo Nordisk, the market has recalibrated shares following a 29% decline over the past 12 months. Pfizer, meanwhile, trades at a forward P/E of 8x as it works to transition away from its pandemic-era revenue reliance.
Novo Nordisk is a Danish ADR. Investors should be aware that dividends are subject to foreign withholding tax at the source before reaching brokerage accounts.
What Is the Growth Case for Novo Nordisk?
Novo Nordisk’s valuation reflects a business generating a 71% return on equity and a 62% operating margin, despite trading at a trailing P/E of 12. The primary growth engine is the oral version of Wegovy. As reported by 24/7 Wall St., the drug captured 65% of new U.S. prescriptions in its category during its first quarter, generating $2.26 billion. CEO Mike Doustdar noted the tablet is now used by more than one million patients. However, the company faces a significant margin risk: U.S. list price cuts of approximately 50% for Wegovy and 35% for Ozempic are scheduled for January 2027.
How Is Pfizer Navigating Its Post-COVID Transition?
Pfizer is focusing on pipeline conversion and cost-efficiency to offset the decline in its COVID-19 franchises. Comirnaty and Paxlovid sales fell 59% and 63% respectively in Q1 2026. To counter this, the company is prioritizing its core portfolio, where products like Padcev (up 39%) and Nurtec (up 41%) are seeing operational growth. According to 24/7 Wall St., Pfizer has secured a Vyndamax patent settlement extending U.S. exclusivity to June 2031. CEO Albert Bourla has expressed confidence in the company’s oncology and obesity assets, with 20 pivotal studies planned for 2026.
| Metric | Novo Nordisk (NVO) | Pfizer (PFE) |
|---|---|---|
| Forward P/E | 14x | 8x |
| Dividend Yield | Varies (ADR) | 7.23% |
What Should Investors Watch in August?
The window for positioning is narrow, as both companies are set to report Q2 earnings in early August 2026. Novo Nordisk’s performance will be evaluated on whether the volume of its oral Wegovy can offset looming price cuts. Pfizer’s results will be measured against its ability to execute on oncology and obesity pipeline developments. While Novo offers optionality in the GLP-1 market, Pfizer provides a 7.23% dividend yield supported by established products like Eliquis.
Monitor the net debt to EBITDA ratio. Pfizer currently sits at 3.26x, which has led management to state that no share repurchases are anticipated in 2026.
Frequently Asked Questions
Why are Pfizer’s earnings and revenue figures so volatile?
Pfizer’s recent financial results have been heavily influenced by the sharp decline in COVID-19-related product sales, specifically Comirnaty and Paxlovid, which saw double-digit percentage drops in Q1 2026.
What is the biggest risk for Novo Nordisk investors?
The primary risk is the compression of cash flow resulting from planned U.S. price cuts for Wegovy and Ozempic, combined with the failure of the CagriSema drug to meet primary endpoints in the REDEFINE 4 obesity trial.
When do these companies report their next earnings?
Pfizer is scheduled to report Q2 earnings on August 4, 2026, followed by Novo Nordisk on August 5, 2026.
For questions regarding this report or to request corrections, please contact the editorial team at 24/7 Wall St.



